This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents investments accounted for under the cost method of accounting as of the balance sheet date.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 6
-Subparagraph a

+ Details

Name:	us-gaap_CostMethodInvestmentsFairValueDisclosure
Namespace Prefix:	us-gaap
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

This element represents a certain statement of financial position asset caption which represents a class of assets, or which may include an individual asset, measured at fair value on a recurring basis.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32
-Subparagraph a

+ Details

Name:	us-gaap_FairValueMeasuredOnRecurringBasisInvestments
Namespace Prefix:	us-gaap
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.

+ Details

Name:	us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix:	us-gaap
Data Type:	us-types:percentItemType
Balance Type:	na
Period Type:	instant

Fair Value Measurements (Details Textuals) (USD $)	Jun. 30, 2011	Dec. 31, 2010	Jun. 30, 2011 DiagnoCure, Inc. [Member]	Apr. 30, 2009 DiagnoCure, Inc. [Member]	Jun. 30, 2011 Pacific Biosciences [Member]	Jun. 30, 2010 Pacific Biosciences [Member]	Jun. 30, 2011 Roka Bioscience, Inc. [Member]	Apr. 30, 2011 Roka Bioscience, Inc. [Member]	Sep. 30, 2009 Roka Bioscience, Inc. [Member]	Jun. 30, 2011 Qualigen, Inc. [Member]
Cost method								19.00%	19.90%
Investment at Fair Value	$ 352,726,000	$ 429,965,000			$ 38,300,000
Cost Method Investments, Asset			$ 5,000,000	$ 5,000,000		$ 50,000,000	$ 4,700,000	$ 4,000,000		$ 5,400,000